Portola Pharmaceuticals will begin the first of multiple small Phase III trials of its Factor Xa inhibitor antidote andexanet alfa, or PRT-4445, the only universal antidote currently in clinical development. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb and Pfizer's apixaban, or Eliquis. Portola has several small late-stage trials planned for the experimental blood thinner antidote and various inhibitors.

Related Summaries